Select sodium channel blockers have anti-diabetic effects

Select sodium channel blockers have anti-diabetic effects

(HealthDay)—Blockade of voltage-gated sodium channels (NaChs) in pancreatic α cells has anti-diabetic effects, according to research published online May 8 in Diabetes.

Arvinder K. Dhalla, Ph.D., of Gilead Sciences in Fremont, Calif., and colleagues tested the hypothesis that the mechanism by which ranolazine, a NaCh blocker approved for use in angina, exerts anti-diabetic effects is inhibition of glucagon release through blockade of sodium channels in α cells.

The researchers found that ranolazine causes blockade of in pancreatic α cells, inhibits their , and reduces the release of glucagon. The release of glucagon in human pancreatic islets is mediated by the Nav1.3 isoform. In animal models, ranolazine and a more selective sodium channel blocker, GS-458967, reduced postprandial and basal glucagon levels; these changes were associated with a reduction in hyperglycemia.

"The findings from the present study suggest that inhibition of α-cell INa could become an attractive drug target for combination with other classes of anti-diabetic agents," the authors write.


Explore further

Scientists identify third critical hormone in Type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Diabetes

Copyright © 2014 HealthDay. All rights reserved.

Citation: Select sodium channel blockers have anti-diabetic effects (2014, May 15) retrieved 23 February 2020 from https://medicalxpress.com/news/2014-05-sodium-channel-blockers-anti-diabetic-effects.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments